Lampl C, Huber G, Haas S, Rittberger E, Diener H C
Department of Neurology and Pain Medicine, Konventhospital Barmherzige Brüder, Linz, Austria.
Cephalalgia. 2008 Oct;28(10):1031-8. doi: 10.1111/j.1468-2982.2008.01642.x. Epub 2008 Jul 9.
The aim of this study was to determine whether in migraine patients with and without aura early treatment with various triptans leads to differences in pain reduction after 1 h and in modulating cutaneous allodynia. Thirty-six patients with early manifestation of a clinically recognizable allodynia of the face and non-responders to earlier treatment with sumatriptan 100 mg were included. Patients were randomized to six triptan treatment groups. Significant pain reduction was seen only in the group receiving zolmitriptan nasal spray 5 mg with a mean visual analogue scale (VAS) score of 3.8 (s.d. 1.2) at baseline and 2.4 (s.d. 1.3; P = 0.015) at 1 h after using the triptan and was thus a predictor of a VAS score 3 within 1 h. The study results indicate that migraine headache intensity can be reduced within 1 h by using zolmitriptan 5 mg nasal spray in spite of the presence of early cutaneous allodynia.
本研究的目的是确定在有先兆和无先兆的偏头痛患者中，早期使用各种曲坦类药物治疗是否会导致1小时后疼痛减轻以及调节皮肤异常性疼痛方面存在差异。纳入了36例面部临床可识别的异常性疼痛早期表现且对100 mg舒马曲坦早期治疗无反应的患者。患者被随机分为六个曲坦类药物治疗组。仅在接受5 mg佐米曲坦鼻喷雾剂的组中观察到显著的疼痛减轻，基线时平均视觉模拟量表（VAS）评分为3.8（标准差1.2），使用曲坦类药物后1小时为2.4（标准差1.3；P = 0.015），因此是1小时内VAS评分为3的预测指标。研究结果表明，尽管存在早期皮肤异常性疼痛，但使用5 mg佐米曲坦鼻喷雾剂可在1小时内减轻偏头痛的头痛强度。
